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Existence and Function of Renin-Angiotensin System in Renal Interstitial Fibroblast
Tomohiro Kikuta (Department of Nephrology, Saitama Medical School, Moroyama, Iruma-gun, Saitama 350 -0495, 
Japan)
 
　Tubulointerstitial fibrosis (TIF) is considered a valid marker of progression of diabetic and non-diabetic 
nephropathy, that correlates negatively with creatinine clearance (CCr), and functional outcome. Since a number 
of clinical trails have revealed that angiotensin converting enzyme inhibitors (ACEi) slowed the rate of decline of 
renal function in proteinuric patients, it is suggested that ACEi can directly and/or indirectly affect TIF. Therefore, 
to test this hypothesis, we performed a prospective study for 3 years focusing on the effects of ACEi on functional 
outcome of patients with IgA nephropathy (IgAN) in relation to the degree of TIF. In the control group treated 
with amlodipine, the degree of TIF was negatively correlated with the reduction rate of CCr (dCCr), which was 
consistent with previous observation. By contrast, in the group treated with ACEi, the dCCr index was attenuated 
compared with the controls, and there was no correlation between the degree of TIF and the dCCr index. The 
latter suggested that ACEi had independent effects on renal fibrogenesis. Subsequently, we performed in vitro 
experiments to test whether angiotensinⅡ(AngⅡ) and aldosterone (ALD) had direct profibrotic ef fects on 
cultured human renal fibroblasts. Human renal fibroblasts expressed AngⅡ type 1 receptor (AT1R) in vivo and in 
vitro. AngⅡ stimulated fibroblast proliferation, and typeⅠcollagen production of human renal fibroblasts via AT1R, 
especially in fibroblasts derived from a fibrosing kidney; this effect was partially mediated by secreted TGF-β. 
ALD could also promote proliferation of fibrosis-derived fibroblasts. In conclusion, ACEi can efficaciously retard 
the progression of IgAN with and without TIF equally, which is supposed to be partially due to its direct effects on 
renal fibrogenesis. 
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クローナルIgG（1:100, Santa Cruz Biotechnology, Santa 
Cruz, CA, U.S.A.），抗AT2Rウサギポリクローナル
IgG（1:100, Dr. Robert M. Careyより供与 , University 
of Virginia Health System, Charlottesville, VA, U.S.A.），
二次抗体としてはビオチン化した抗ウサギIgGヤギポ
リクローナルIgG（1:500, Santa Cruz Biotechnology）を，
シグナルの可視化にはVectastain ABC Standard Kit






（HC-2500, Fuji Film Company, Tokyo）を用いてコン
ピューターに取り込み，画像処理ソフト（Mac SCOPE, 






Frank Strutz博士（Department of Nephrology, Georg 
August University, Germany）より御供与頂いた12)．
Dulbecco’s modified Eagle’s medium（DMEM）に10％














拮抗薬（CGP-48933, Novartis Pharma AGより供与 , 
Basel, Switzerland）またはAT 2R拮抗薬（PD-123319, 




2回洗浄し，細胞を1M NaOH/0.1％ Triton X-100で溶
解した．放射活性はガンマカウンターで測定した．







んだ1.5 M KOH/60 mM Hepes バッファーを滴下し
てpH 7.5に調整した．中和されたサンプルでd-myo-
IP3[3H]assay system（Biotrak, Amersham Pharmacia 



















解バッファーにて（10 mM Tris, pH 7.5, 125 mM NaCl, 
0.1％ Nonidet-P40, 1％ SDS）細胞のホモジネートを
得た．同検体をグラスファイバーフィルタ （ーGF/C, 
Whatman International, Kent, UK）に吸収させ，20％
trichloroacetic acid（TCA），5％ TCA，80％エタノー
ルで洗浄し，乾燥後，フィルターに残った放射活性を
シンチレーションカウンタ （ーBeckman Instruments, 
Palo Alto, CA, U.S.A.）で測定した．
<I 型コラーゲン（COL I）産生量測定> Hk173 と Hk188 











ファ （ー10％脱脂粉乳 , 0.1％ Tween20, 0.05％ NaN3を
含むPBS）で室温，30分間ウェル表面をブロッキング
し，つづいて同ブロッキングバッファーに希釈した
抗 I型コラーゲンウサギポリクローナル IgG（1:3000, 
Chemicon International, Temecula, CA, U.S.A.）と室温
30分間反応させた．洗浄後同様に希釈したアルカリ
フォスファターゼ標識抗ウサギIgG抗体，および基





























Table 1. Demographic data   *means p＜0.05 vs year 0
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あった．TIF indexと蛋白尿の間には弱い正の相関を





































Fig. 2. Clinical and pathological correlations. a. In both 
groups at baseline, TIF index shows a weak, positive 
correlation with urinary protein excretion. b. At the end of 
3-year follow-up, in the CCB group, TIF index was found to be 
positively correlated with dCCr index. By contrast, in the ACE 
inhibitor group, there is no correlation between TIF index and 
dCCr index.
Fig. 3. Human renal fibroblasts possess AngⅡ type 1 
receptors. Renal fibroblasts Hk173, derived from a normal 
kidney and Hk188, derived from a fibrosing kidney possess 
AT1R binding sites. Displacement of [125I]-[Sar1, Ile8]Ang
Ⅱ binding from renal fibroblasts. Competition of the binding 
of [125I]-[Sar1, Ile8]AngⅡ by increasing concentration of 
unlabeled AngⅡ(a), CGP48933(b) or PD123319(c). Data 
represent the mean of 3 independent experiments.
Fig. 1. Representative renal histopathology of IgAN with TIF. 
a. The area of TIF is shown in blue on the MT-stained section. 
(x 100, MT) b. Most of the blue area in Fig. 1a turns green, 
and the green area is quantitatively evaluated by an image 
analyzer. The TIF index is 11.4％ in this case. (x 100, MT) c. 
Immunohistochemistry with anti- AT1R antibody revealed that 
not only glomerular, vascular and tubular cells, but also some 
of interstitial fibroblast-like cells are positive for AT1R (arrows) 
within the TIF of IgAN. (x 100, AEC) d. A negative control for 



























Fig. 7. Mitogenic effects of ALD on renal fibroblasts. ALD at 
30 and 100 nM dose -dependently increased [3H]thymidine 
incorporation into Hk188, but not into Hk173 cells. This 
mitogenic ef fect was blocked by SPL. Data represent the 
mean of 3 independent experiments.
Fig. 4. Stimulation of renal fibroblasts with AngⅡ evokes IP3 
response. AngⅡ at 10-6M induced significant IP3 responses in 
both Hk173 and Hk188, and these responses were abolished 
by pre-treatment with CGP48933. Data represent the mean of 
3 independent experiments.
Fig. 5. Mitogenic effects of AngⅡ on renal fibroblasts. Ang
Ⅱ at 10-6 and 10-5 M significantly increased [3H]thymidine 
incorporation into both Hk173 and Hk188 cells; this 
was blocked by CGP48933 and par tially attenuated by a 
neutralizing anti-TGF-β antibody. Data represent the mean of 
3 independent experiments.
Fig. 6. Ef fects of AngⅡ on COLⅠ production in renal 
f ibroblasts .  AngⅡ a t  10 - 6M signi f icant ly  enhanced 
COLⅠ production in Hk188, but not in Hk173 cells. This 
enhancement was blocked by CGP48933 and par tially 
attenuated by a neutralizing anti-TGF-β antibody. Data 












































































































































































（Toronto 2000, San Francisco 2001）において発表した．
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